Centene (CNC)
(Delayed Data from NYSE)
$70.84 USD
+0.01 (0.01%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $70.82 -0.02 (-0.03%) 7:22 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.84 USD
+0.01 (0.01%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $70.82 -0.02 (-0.03%) 7:22 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Varian (VAR) Rides on Diverse Product Line, Competition Rife
by Zacks Equity Research
Varian Medical (VAR) has a strong international presence and growing proton therapy market. However, intense competition adds to woes.
Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line
by Zacks Equity Research
Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.
Cardiovascular Systems Gains From 510K for OrbusNeich Device
by Zacks Equity Research
Cardiovascular Systems (CSII) to distribute limited editions of both 1.0-4.0mm Sapphire II PRO and 2.0-4.0mm Sapphire NC Plus non-compliant coronary balloons post the product launches in the market.
Universal Health (UHS) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Solid segmental performance drives Universal Health's (UHS) fourth-quarter results.
Community Health's (CYH) Q4 Loss Narrower Than Expected
by Zacks Equity Research
Lower admission hurts Community Health's (CYH) fourth-quarter results.
Veeva Systems (VEEV) Q4 Earnings Top, FY19 View Promising
by Zacks Equity Research
Veeva Systems (VEEV) continues to witness year-over-year growth on earnings and revenues backed by the company's consistent efforts in product innovation and launches via R&D.
Zacks.com highlights: Centene, Andersons, Builders FirstSource, United Continental Holdings and Dillard's
by Zacks Equity Research
Zacks.com highlights: Centene, Andersons, Builders FirstSource, United Continental Holdings and Dillard's
Envision Healthcare (EVHC) Q4 Earnings Beat, Revenues Rise
by Zacks Equity Research
Envision Healthcare (EVHC) earnings benefited from higher revenues partly offset by an increase in expenses.
Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition
by Zacks Equity Research
Allscripts' (MDRX) promising fourth-quarter results and international hold are encouraging. Integration risks and cutthroat competition are likely to mar prospects.
Masimo Products to Boost India-Based NU Hospitals' Systems
by Zacks Equity Research
Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.
Tenet Healthcare (THC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Strong segmental performances along with solid expense management aid Tenet Healthcare's (THC) Q4.
5 Stocks to Bet on Following Recent Broker Rating Upgrades
by Zacks Equity Research
With multiple earnings reports flooding the market, determining the outperformers is by no means an easy task for individual investors.
LifePoint Health (LPNT) Q4 Earnings Miss on Lower Revenues
by Zacks Equity Research
LifePoint Health (LPNT) fails to beat the earnings and revenue estimates in the fourth quarter. Equivalent admissions decline 3% year over year.
Here's Why You Must Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.
Varian (VAR) Acquires Evinance to Boost Oncology Segment
by Zacks Equity Research
Varian Medical Systems (VAR) acquires Evinance to improve cancer care through CDS software. The company also expects to gain from flagship ARIA's recent certification.
Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price
by Zacks Equity Research
Express Scripts (ESRX) expands group purchasing effort with Walgreens Boots Alliance to simplify supply chains and make specialty drugs affordable.
International Business Aids NuVasive, Pricing Woe Remains
by Zacks Equity Research
NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.
Cerner Partnering With Surescripts to Revamp EHR Platform
by Zacks Equity Research
Cerner (CERN) will introduce Surescripts' Real-Time Prescription Benefit functionality into "Cerner Millennium's" EHR platform to help clients curtail escalating healthcare costs.
BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
NuVasive's SpineTRACK Registry Gains New CMS Designation
by Zacks Equity Research
NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.
Luminex (LMNX) Banks on Solid Product Line, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis
by Zacks Equity Research
Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.
Hologic Banks on Diagnostics, GYN Surgical Prospects Bright
by Zacks Equity Research
Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.
Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too
by Zacks Equity Research
CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.
Inogen (INGN) Gains on Diverse Product Line, Competition Rife
by Zacks Equity Research
Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.